The development of cancer treatments often focuses predominantly on eradicating tumors, but Ben Zeskind, CEO of Immuneering, argues that prioritizing patient quality of life is equally essential. During an interview at the JP Morgan Healthcare Conference in San Francisco last month, Zeskind highlighted his company’s groundbreaking approach to treating pancreatic cancer, revealing that their drug has effectively doubled overall survival rates while maintaining patient independence and enhancing quality of life.
Zeskind elaborated on the innovative mechanism of action employed by Immuneering’s drug, atebimetinin. Unlike traditional small molecule drugs that aim for a complete blockage of cancer-causing pathways, atebimetinin utilizes a technique known as deep cyclic inhibition. This method targets these pathways intermittently, allowing for a more nuanced approach to treatment.
“This strategy can lead to improved outcomes for patients, not only in terms of survival but also in preserving their daily lives,” Zeskind stated. The feedback from oncologists who have observed promising results in their patients supports this assertion. Many have noted significant improvements in both health and well-being among those treated with the new drug.
Looking Ahead to 2026
As the conversation shifted towards the future of oncology, Zeskind shared insights on the evolving landscape of cancer treatment. He expressed optimism about the potential applications of their technology beyond pancreatic cancer, suggesting that the principles behind deep cyclic inhibition could be adapted to other cancer types.
Zeskind’s vision for 2026 encompasses a shift in how cancer therapies are developed and administered, emphasizing the importance of patient-centered care. “Our goal is to ensure that patients not only live longer but also lead fulfilling lives during their treatment,” he explained. This perspective reflects a growing trend within the medical community, where the focus is increasingly on the holistic well-being of patients rather than solely on survival statistics.
In conclusion, Immuneering’s approach, as articulated by Zeskind, marks a significant step forward in cancer treatment. By prioritizing both survival and quality of life, the company is setting a new standard in oncology, one that could reshape patient experiences and outcomes in the years to come.
